Skip to content

Mistras Group MG Granted (in shares)

Granted (in shares) at other companies

CNB Financial logo
CNB FinancialCCNE
0
Wingstop logo
WingstopWING
0
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
1.5M-12.6%
LivaNova logo
LivaNovaLIVN
957.7K+31.3%
The Hanover Insurance Group logo
The Hanover Insurance GroupTHG
148.1K+5.5%
Genpact logo
GenpactG
0

Other financials

Income statement

See full
Revenue$169.0M+4.6%
Gross profit$50.2M+8.4%
Operating income$4.7M+563%
Net income$2.4M+175%
EPS (diluted)$0.07+170%

Balance sheet

See full
Cash & equivalents$25.0M+34.8%
Total debt$216.7M+5.8%
Total equity$233.2M+17.4%
Total assets$572.7M+8.7%

Cash flow

See full
Operating cash flow$2.8M-50.2%
CapEx$6.0M+31.0%
Free cash flow-$3.2M-390%

Valuation

See full
Market cap$597.52M+153%
Enterprise value$789.23M+86.6%
P/E26.7×+10.7×
P/S0.8×+0.5×

Profitability

See full
Gross margin31.5%+1.8pp
Operating margin6.3%+1.6pp
Net margin3.1%+1.0pp
FCF margin0.6%-4.8pp

Returns & leverage

See full
Return on equity10.4%+2.7pp
Debt / equity0.9×-0.1×
Current ratio1.8×+0.3×

Where this comes from

Reported directly by Mistras Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.

The official record: Mistras Group’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mistras Group's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mistras Group's granted (in shares)?
Mistras Group (MG) reported granted (in shares) of 0 in Q1 2026.
How has Mistras Group's granted (in shares) changed year-over-year?
Mistras Group's granted (in shares) decreased by 100.0% year-over-year, from 375K to 0.
What does granted (in shares) mean?
The total number of stock option shares granted to employees and directors during the reporting period. This metric provides insight into the company's equity-based incentive strategy and potential future dilution.